|
aap Implantate AG's 9-month report shows sales stabilized, results improved and equity ratio increased to 74%
aap Implantate AG, a medical technology company specialized in healing bone fractures, joint replacements and bone growth and replacement substances, achieved for the first three quarters of the business year 2004 revenues of EUR 8.6 million, par with previous year's EUR 8.7 million. In the third quarter, company´s first complete quarter after initiation of balance sheet restructuring measures, revenues increased by 9% compared to the previous years period to EUR 2.8 Million and therefore compensated first half year´s reduced revenues.
Due to third-quarter restructuring measures (a EUR 9.7 million capital increase, debt buy-backs and waivers), the company achieved a restructuring profit of EUR 6.2 million. The extraordinary result in the reporting period was EUR 4.5 million, leading to a EUR 1.3 million surplus (previous year: EUR minus 1.9 million). The equity ratio increased to 74% (previous year: 25%), with a balance sheet total of EUR 23.3 million (previous year: EUR 26.7 million).
Disregarding the extraordinary result, aap Implantate AG's EBITDA in the first nine months of 2004 was EUR 1.0 million (previous year: EUR 872,000). EBIT at EUR minus 187,000 was well above the previous year's EUR minus 1.7 million. For the third quarter the company achieved an operating result of EUR 16,000 (Q3´03: EUR minus 721,000).
For further information, please contact:
aap Implantate AG | | | Lorenzweg 5 | | | D-12099 Berlin | | | X | | | Oliver Bielenstein | Nanette Hüdepohl | | Director/CFO | Investor & Public Relations | Tel.: +49 30 750 19 - 140 | Tel.: +49 30 75019 - 133 | Fax: +49 30 750 19 - 290 | Fax: +49 30 75019 - 290 | | X | | | WKN 506660, ISIN DE0005066609 | | | Prime Standard/Regulated Market | | | Traded at all German Stock Exchanges | |
|
Print this page
